CA2140011A1 — Ovulation inhibiting agent for hormonal contraception

USPTO Abstract

A B S T R A C T Ovulation inhibiting agent for hormonal contraception with two hormonal components arranged in spatially separated manner in a packaging unit for time-sequential oral administration and which in each case comprise a plurality of spatially separated and individually removable hormone daily units housed in the packaging unit, one hormone component (estrogen component) essentially exclusively containing an estrogen product bringing about a disturbance of follicular maturation and the other hormone component (estrogen - gestagen component) in combination contains an estrogen product and a gestagen product in a dosage at least adequate for ovulation inhibition, characterized in that it alternately comprises an estrogen component or components with 5 to 14 daily units and an estrogen - gestagen component or components with 23 to 14 daily units, that the number of estrogen and estrogen gestagen components is the same, that the number of daily units in the estrogen component or components is smaller than the number of daily units in the estrogen - gestagen component or components and that in the case that ethynylestradiol is used as the estrogen product the ethynylestradiol dose per daily unit is max 30 µg.